• Explore /
  • Poster
  • / Phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2).

Phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2).

Abstract Poster

Authors

Benjamin Weinberg

Benjamin Adam Weinberg

Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Benjamin Adam Weinberg , Hongkun Wang , Katrina Pedersen , Amikar Sehdev , Max W. Sung , Jimmy J. Hwang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04005339

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS593)

Abstract #

TPS593

Poster Bd #

P6

Abstract Disclosures

Similar Posters

Poster

2017 Gastrointestinal Cancers Symposium

A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.

A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.

First Author: Naminatsu Takahara

First Author: Choong-kun Lee

First Author: Medhavi Gupta

First Author: Thomas Jens Ettrich